CN108409836A - A kind of polypeptide and application thereof - Google Patents
A kind of polypeptide and application thereof Download PDFInfo
- Publication number
- CN108409836A CN108409836A CN201810214130.3A CN201810214130A CN108409836A CN 108409836 A CN108409836 A CN 108409836A CN 201810214130 A CN201810214130 A CN 201810214130A CN 108409836 A CN108409836 A CN 108409836A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- cell
- application
- tumor
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention belongs to biomedical sectors, and in particular to a kind of polypeptide and application thereof.The amino acid sequence of the polypeptide is：DYHDPSLPTLRK（SEQ ID No.1）.It specific can be combined with Human colorectal cancer cells targeting, and people's normal intestinal epithelial cell is not influenced, and also there is recognition reaction to human pancreatic cancer cell, breast cancer cell and ovarian cancer cell, this plays an important roll in the early diagnosis of colorectal cancer, cancer of pancreas, breast cancer and oophoroma and the research and development of targeted drug etc..
Description
Technical field
The invention belongs to biomedical sectors, and in particular to a kind of to Human colorectal cancer cells, pancreatic cancer cell, breast cancer
Cell or ovarian cancer cell have polypeptide of targeting and application thereof.
Background technology
Colorectal cancer is one of most common malignant tumour of digestive system, according to China's Incidences in 2016 and extremely
Analysis big data research report is died, annual 33.1 ten thousand people of new cases of colorectal cancer in China, incidence is in whole malignant tumours
In be number four position；The patient for dying of the disease every year has 15.9 ten thousand people, the death rate then to occupy cancer mortality reason the 5th.In U.S.
State's colorectal cancer becomes the high malignant tumour of incidence third, has more than 10.6 ten thousand people every year and is diagnosed and suffers from colorectal cancer.With me
State is different, although the incidence of U.S.'s colorectal cancer is high, the death rate declines year by year, this is mainly attributed to more and more tie
The carcinoma of the rectum is discovered in an early phase, to obtain the chance being cured.5 years survival rates of early stage colorectal cancer patients reach 90%,
And metastatic or late cancer are only 10%.In clinical practice, it has been recognized that early diagnosis is expected to realize personalized treatment,
Help to improve long-term final result.
Currently, the screening mode of colorectal cancer, such as occult blood test, Fecal Immunochemical Test and colonoscopy,
May not be optimal, these methods may can't detect neoplastic lesion or carry out unnecessary endoscopic diagnosis.And
Hypogenetic lesion may be difficult to differentiate between with the relevant epithelium regeneration of inflammation.In addition, being also possible to will appear in colonoscopy
Adverse events, such as perforation.Therefore, the detection of early stage colorectal cancer, the sensitive diagnostic techniques of exploitation, targeted therapy is the weight of research
Point.
Existing anticancer drug, which mainly has, extracts anticancer active constituent, anticancer drug in Metal Anticancer Drug, natural products
Five class such as targeting preparation, genetically engineered drug, Studies of Nano-controlled Release Anticancer Drugs, these drugs usually larger, medicine with toxic side effect
Object dosage is big, easy tos produce the shortcomings of drug resistance day after tomorrow, is impacted to the treatment of tumour.
Display technique of bacteriophage is a kind of technology of important screening intermolecular interaction of molecular biology field.Phagocytosis
The cardinal principle of body display technology is that the gene of target gene or coding protein and polypeptide is cloned by technique for gene engineering
On the appropriate location of phage surface protein gene, allows its amplification with phage DNA and express in phage surface, due to
The compatibility of foreign gene and phage gene, the expression product polypeptide or protein of foreign gene still can keep its original
Space structure and corresponding biological activity.Then, we carry out subtrahend screening using target cell or target molecule to bacteriophage, most
Filter out the purpose bacteriophage that can be specifically bound with target cell or target molecule from phage peptide library eventually, and to its DNA into
Row sequencing, you can obtain the coded sequence of corresponding polypeptide.This technology realize protein or polypeptide gene type and phenotype it
Between contact, and with easy to operate, can high-throughput detection the characteristics of, to be combined as screening tumor cell specific
The efficient means of peptide, the targeting vector research for the early detection and drug therapy of tumour provide new direction.
Invention content
The purpose of the present invention is to provide a kind of polypeptides, specific can be combined with Human colorectal cancer cells targeting, and to people
Normal intestinal epithelial cell does not influence, and also has to human pancreatic cancer cell, human breast cancer cell and Proliferation of Human Ovarian Cell and know
It does not act on, this plays an important roll in the early diagnosis of colorectal cancer and the research and development of targeted drug etc., and to cancer of pancreas, breast
Gland cancer, the early diagnosis of oophoroma and targeted drug research and development also play an important roll.
This experiment is control with people's normal intestinal epithelial cell, using Human colorectal cancer cells HCT116 to phage display
Peptide library carries out subtrahend screening, and the sun that cell-specific is combined can be occurred with colorectal cancer cell by being picked out with blue and white screening experiment
Property phage clone, the specificity for being used in combination ELISA experimental verifications bacteriophage to be combined with colorectal cancer cell.Then with Escherichia coli
For carrier, its DNA is extracted after amplification purification bacteriophage and is sequenced to get to specificity knot can occur with colorectal cancer cell
The coded sequence of the polypeptide of conjunction, and the positive polypeptides of artificial synthesized fluorescent marker carry out fluorescent marker-polypeptide and Human colorectal carcinoma
The verification of the combination of cell and tissue, and then provide experiment basis for the early diagnosis and targeted therapy of colorectal cancer.
To achieve the goals above, the present invention adopts the following technical scheme that：A kind of polypeptide, the polypeptide are the ammonia of (1) polypeptide
Base acid sequence is：DYHDPSLPTLRK (SEQ ID No.1), in the peptide molecule of (2) described in (1) by missing, be inserted into or
It replaces one or several amino acid and there is the polypeptide derivative of identical biological function with the peptide molecule described in (1).
The polypeptide has targeting to tumour cell, is combined with tumor cell specific.
The tumour cell is that Human colorectal cancer cells, human pancreatic cancer cell, human breast cancer cell or human ovarian cancer are thin
Born of the same parents.
Application of the polypeptide in preparing tumor diagnosis kit includes the polypeptide or polypeptide coupling in the kit.
Polypeptide is being prepared for the application in tumor, the drug include the polypeptide with pharmaceutical activity at
Point, or comprising the polypeptide and pass drug carrier.The drug is acceptable dosage form in any pharmacotherapeutics, and the drug is preferred
Dosage form be ejection preparation.
The drug is dosage acceptable in any pharmacotherapeutics.
Compared with prior art, effect of the invention is that：The present invention using display technique of bacteriophage have it is easy to operate,
The elutriation of high throughput, high efficiency can screen mimic epitope, displayed polypeptides or protein and it includes the bases inside bacteriophage
The advantages that being easy to purifying because of the connection of password, recombinant phage.We, which use, enables the peptide that phage display technique is filtered out
It is specifically bound with Human colorectal cancer cells, and with normal enterocyte without specific effect, and function and effect are apparent.
And it is demonstrated experimentally that the peptide also has targeting with human pancreatic cancer cell, human breast cancer cell and Proliferation of Human Ovarian Cell.
Description of the drawings
Fig. 1 is the positive bacteriophage DNA sequencing result with Human colorectal cancer cells HCT16 specific bindings.
Fig. 2 is the target of FITC-DK12 and people normal intestinal epithelial cell HIEC and Human colorectal cancer cells HCT116, SW620
To combination.
Fig. 3 is FITC-DK12 and people's ovarian epithelial cell HOSEpiC and human ovarian cancer gland cell OVCAR-3, SK-OV-3
Targeting combination.
Fig. 4 is FITC-DK12 and Human embryo pancreatic tissue derived cell CCC-HPE-2 and human pancreatic cancer cell MIA
The targeting combination of PaCa-2.
Fig. 5 is FITC-DK12 and human mammary epithelial cell MCF-10A and human breast cancer cell line Bcap-37, MDA-MB-
The targeting combination of 23110A.
Fig. 6 is the targeting combination of FITC-DK12 and Human colorectal carcinoma and cancer beside organism.
Fig. 7 is the targeting combination of FITC-DK12 and mice with tumor Human colorectal cancer cells HCT116.
Specific implementation mode
It is as described below to be merely a preferred embodiment of the present invention, it is not intended to restrict the invention, for the skill of this field
For art personnel, the invention may be variously modified and varied.All within the spirits and principles of the present invention, any made by repair
Change, equivalent replacement, improvement etc., should all be included in the protection scope of the present invention.
Embodiment 1
1. experiment material
1.1 phage peptide libraries, cell and host strain.
12 peptide library of bacteriophage, E. coli ER2738, people's normal intestinal epithelial cell HIEC, Human colorectal carcinoma are thin
Born of the same parents HCT116 and SW620, people's ovarian epithelial cell HOSEpiC, people's ovary adenocarcinoma cells OVCAR-3 and SK-OV-3, Human embryo pancreas
Glandular tissue derived cell CCC-HPE-2, human pancreatic cancer cell MIA PaCa-2, human mammary epithelial cell MCF-10A, human breast carcinoma
Cell MCF-7 and MDA-MB-231, mice with tumor, Human colorectal carcinoma tissue.
1.2 experiment reagent
DEME culture mediums, RPMI-1640 culture mediums, trypsase, FITG label rabbit-antis mouse, fetal calf serum, yeast powder, egg
White peptone, agar powder, tetracycline storage liquid, Tween-20 (tween-20), bovine serum albumin BSA, the extraction of M13 phage single-chain DNAs
Kit, IPTG, X-gal, PEG-8000, TMB.
1.3 experimental work liquid
1 × PBS, LB liquid medium, LB-Tet solid plates, top agar, IPTG/X-gal working solutions, IPTG/X-
Gal tablets, PEG-NaCl, TBS buffer solution, 0.1%TBST, 0.5%TBST, 4% paraformaldehyde fixer, TBS-NaN3 liquid
Preparation, 3%BSA confining liquids, sodium iodide buffer solution, TE buffer solutions, TMB working solutions, tetracycline store liquid.
2. experimental method
The culture of 2.1 Escherichia coli.
(1) recovery of Escherichia coli：Escherichia coli glycerine frozen stock solution is taken out from -80 DEG C of refrigerators, is taken on a small quantity with oese
It lines on LB/Tet solid plates, then this LB/Tet solid plate is inverted in 37 DEG C of electro-heating standing-temperature cultivator and is cultivated
Overnight, picking single bacterium colony when use.
(2) culture of Escherichia coli：10ml LB/Tet fluid nutrient mediums, picking large intestine bar are added in 15ml centrifuge tubes
Bacterium single bacterium colony is added thereto.Then centrifuge tube is placed in overnight incubation in constant temperature oscillator, when the OD600 values of bacterium solution are 0.5
It can carry out related experiment.
The subtrahend of 2.2 phage display peptide libraries screens.
(1) prepare cell：First 6 well culture plates are pre-processed through poly-lysine, take Human colorectal cancer cells HCT116 and
People normal intestinal epithelial cell HIEC, respectively with being laid on after trypsin treatment wherein, culture is adherent to cell success and grows shape
It is screened after state is good.
(2) bacterium solution is prepared：On the screening same day, Escherichia coli ER2738 is inoculated in 20ml LB/Tet fluid nutrient mediums, is set
The shake culture in 37 DEG C of constant temperature oscillators, when the OD600 values of bacterium solution are 0.5, the bacteriophage for expanding screening elution.
(3) free serum culture：Cell culture medium is sopped up, serum free medium is added after washing 1 time with PBS, is placed in and is connected with
1h in 37 DEG C of constant temperature cell incubators of 5%CO2.
(4) it washs:Confining liquid is sopped up, is more lightly washed 5 times with 0.1%TBST, is both needed to rotate the bottom so that micropore every time
Portion and edge are all washed, drying.0.5%TBST, 1.0%TBST are used respectively when being screened to the 2nd, 3 wheels.
(5) closing cell:Cell culture medium is sopped up, tablet is inverted in firmly to clap on clean paper handkerchief and gets rid of removal remaining
Culture medium is closed Human colorectal cancer cells HCT116 and people normal intestinal epithelial cell HIEC with the culture medium containing 1%BSA, is placed in
It is connected with 1h in 37 DEG C of constant temperature cell incubators of 5%CO2.
(6) it adsorbs:10 μ l of original peptide library are taken, is added in 990 μ l 0.5%BSA/PBS buffer solutions, bacteriophage is diluted
It for 1.5 × 1011pfu/ml, and adds it in closed people's normal intestinal epithelial cell HIEC, 37 DEG C of 1h, absorption can be with
The bacteriophage combined with people's normal intestinal epithelial cell HIEC, leaves and takes supernatant.
(7) it combines:Phage supernatants after absorption are incubated 1h jointly with Human colorectal cancer cells HCT116.
(8) it washs:Unbonded bacteriophage is discarded, microwell plate is inverted on clean paper handkerchief firmly to clap and be got rid of, with removal
The solution of remaining.0.1%TBST board-washings are used as stated above 5 times.
(9) it elutes:0.2M Glycine-HCl (pH2.2) 1mg/mlBSA eluent 1ml are added, shake 10min slowly on ice,
Then eluent is sucked out and is transferred in the 150 μ l neutralizers (1M Tris-HCl, pH9.1) that are ready in advance.
(10) according to above-mentioned steps repetitive operation 2 times.
The titer determination of 2.3 bacteriophages.
By the preheating of IPTG/X-gal tablets in 37 DEG C of electro-heating standing-temperature cultivator；Suitable top agar is taken out in microwave
It is heated in stove, is taken out after it melts completely, 3ml is dispensed in each 10ml centrifuge tubes；Bacteriophage to be screened is carried out etc.
After dilution, after taking 10 μ l to be sufficiently mixed with the Escherichia coli bacteria liquid of 200 μ l and react 5min, it is added in the top agar of 3ml,
Then it is equably layered on the IPTG/X-gal tablets of preheating, the electro-heating standing-temperature cultivator to be condensed for being placed on 37 DEG C is stayed overnight, and is seen
Examine titration results.
The amplification and purifying of 2.4 bacteriophages.
(1) amplification of bacteriophage：20mlLB/Tet fluid nutrient mediums are added in conical flask, then press 1:100 are added greatly
Enterobacteria bacterium solution and bacteriophage to be amplified, are placed in 37 DEG C, 4.5h are acutely shaken in constant temperature oscillator, obtain the amplification of bacteriophage
Liquid.
(2) purifying of bacteriophage：4 DEG C of Phage amplification liquid, the 12000r/min that will be obtained through above-mentioned steps, centrifugation
10min, after taking supernatant and 1/6 volume PEG-NaCl precipitates overnights being added, 12000r/min centrifuges 15min, discards supernatant liquid, uses
TBS buffer solutions precipitate, and give 1/6 volume PEG-NaCl again, are incubated 1h on ice.4 DEG C, 14000r/min, centrifugation
15min is discarded supernatant, and obtained precipitation TBS-NaN3 is dissolved and is placed on 4 DEG C of refrigerators preservations.
The extraction and sequencing of 2.5 positive bacteriophage DNA
(1) 100ul iodide buffer solutions are added in the phages of above-mentioned purifying, add 250ul absolute ethyl alcohols,
It mixes well, room temperature acts on 20min.
(2) it centrifuges：4 DEG C, 14,000rpm, 10min abandon supernatant.
(3) it cleans：Precipitation is washed with 70% ethyl alcohol of 500ul, is dried in vacuo after of short duration centrifugation.
(4) precipitation is resuspended in 30ulTE (10mM Tris-HCl, pH5.0,1mMEDTA) buffer solution, and DNA sequencing template is made
Liquid is sent and Shanghai life work sequencing.
2.6 cellular immunofluorescences are tested
(1) plating cells：It will be on people's normal intestinal epithelial cell HIEC, human colon cancer cell HCT116 and SW620, people's ovary
Chrotoplast HOSEpiC, people's ovary adenocarcinoma cells OVCAR-3 and SK-OV-3, Human embryo pancreatic tissue derived cell CCC-HPE-2,
Human pancreatic cancer cell MIA PaCa-2, human mammary epithelial cell MCF-10A, human breast cancer cell line Bcap-37 and MDA-MB-231 pavings
It is for use in six orifice plates.
(2) fixed：15min is fixed with 4% paraformaldehyde.
(3) it closes：4% paraformaldehyde is discarded, PBS is washed 2 times, and 30min is closed in 37 DEG C with 3%BSA/PBS.
(4) FITC-DK12 is incubated：FITC-DK12,37 DEG C of 1h are added after confining liquid is wiped.
(5) DAPI is dyed：Add 100 μ l of DAPI, room temperature, 15min after washing 3 times with PBS
(6) mounting:After PBS washes 3 times, mounting.
2.7 histogenic immunity fluorescence experiments
(1) piece is baked：60 DEG C, 4~6h
(2) slice dewaxes to water：I 15min of dimethylbenzene → II 15min of dimethylbenzene → I 5min of absolute alcohol → absolute alcohol
The alcohol of II 5min → 95% alcohol of 5min → 85% alcohol of 5min → 75% 5min → distilled water 5min.
(3) it closes：With 3%BSA/PBS 30min is closed in 37 DEG C.
(4) FITC-DK12 is incubated：FITC-DK12,37 DEG C of 1h are added after confining liquid is wiped.
(5) DAPI is dyed：Add 100 μ l of DAPI, room temperature, 15min after washing 3 times with PBS
(6) mounting:After PBS washes 3 times, mounting.
2.8 mice with tumor are tested
(1) lotus knurl：Experiment four week old of nude mice, oxter inoculation human colon cancer cell HCT116 make its tumor formation.
(2) it is imaged：Polypeptide is configured to the solution for standby of 100 μM/ml with PBS, gives lotus knurl tail vein injection FITC-
DK12 polypeptide solution 0.1ml, are imaged on small animal imaging instrument after ten minutes.
3. experimental result
For the targeting phage DNA sequencing result of Human colorectal cancer cells HCT116, as shown in Figure 1, close according to three
The principle of numeral, translates polypeptide sequence：DYHDPSLPTLRK(SEQ ID No.1)(DK12).
Fluorescent marker polypeptide FITC-DK12, with immunofluorescence dyeing test detect the polypeptide respectively with Human colorectal carcinoma, ovum
The targeting combination of nest cancer, cancer of pancreas and breast cancer cell, then further using immunofluorescence dyeing experimental verification, this is more
The targeting binding ability of peptide and Human colorectal carcinoma tissue, and demonstrate the polypeptide and Human colorectal cancer cells using mice with tumor
The targeting of HCT16.As shown in Fig. 2, the polypeptide sequence can be tied with Human colorectal cancer cells HCT116 and SW620 targeting
It closes, and, the two significant difference weaker to normal colonic mucosa epithelial cell HIEC binding abilities；The polypeptide sequence also can simultaneously
Enough and people's ovary adenocarcinoma cells OVCAR-3 and SK-OV-3 targeting combines, and is combined to people's normal ovarian epithelial cell HOSEpiC
Ability is weaker, the significant difference of the two (see Fig. 3)；And the polypeptide sequence also can be with human pancreatic cancer cell MIAPaCa-2
And human breast cancer cell line Bcap-37 and MDA-MB-231 targetings combine, and to Human embryo pancreatic tissue derived cell CCC-HPE-2
It is weaker with human mammary epithelial cell MCF-10A binding abilities, the significant difference of the two (see Fig. 4,5)；Pass through further experiment
Confirm, FITC-DK12 can selectively targeted Human colorectal carcinoma tissue, it is then weaker (see Fig. 6) with the binding force of cancer beside organism,
And there is targeting binding ability with mice with tumor Human colorectal cancer cells HCT116 (see Fig. 7).
SEQUENCE LISTING
<110>Chinese Medical Sciences University
<120>A kind of polypeptide and application thereof
<130> 1
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 12
<212> PRT
<213>Artificial sequence
<400> 1
Asp Tyr His Asp Pro Ser Leu Pro Thr Leu Arg Lys
1 5 10
Claims (10)
1. a kind of polypeptide, which is characterized in that the polypeptide is following arbitrary：
The amino acid sequence of polypeptide is：DYHDPSLPTLRK（SEQ ID No.1）；
（1）In the peptide molecule by missing, be inserted into or replace one or several amino acid and with（1）The polypeptide
Molecule has the polypeptide derivative of identical biological function.
2. polypeptide according to claim 1, which is characterized in that the polypeptide has targeting to tumour cell, thin with tumour
Born of the same parents specifically bind.
3. polypeptide according to claim 1, which is characterized in that the tumour cell is colon cancer cell, cancer of pancreas is thin
Born of the same parents, breast cancer cell or ovarian cancer cell.
4. application of the polypeptide as described in claim 1 in preparing tumor diagnosis kit.
5. application of the polypeptide according to claim 1 in preparing tumor diagnosis kit, which is characterized in that in the reagent
Include the polypeptide or polypeptide coupling in box.
6. application of the polypeptide as described in claim 1 in preparing for tumor.
7. application of the polypeptide according to claim 6 in preparing for tumor, which is characterized in that the drug
Including the polypeptide and active constituents of medicine, or comprising the polypeptide and pass drug carrier.
8. application of the polypeptide according to claim 6 in preparing for tumor, which is characterized in that the drug
For dosage form acceptable in any pharmacotherapeutics.
9. application of the polypeptide according to claim 6 in preparing for tumor, which is characterized in that the drug
Dosage form be ejection preparation.
10. application of the polypeptide according to claim 6 in preparing for tumor, which is characterized in that the medicine
Object is dosage acceptable in any pharmacotherapeutics.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810013702 | 2018-01-08 | ||
| CN2018100137021 | 2018-01-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108409836A true CN108409836A (en) | 2018-08-17 |
| CN108409836B CN108409836B (en) | 2020-04-21 |
Family
ID=63131640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810214130.3A Active CN108409836B (en) | 2018-01-08 | 2018-03-15 | Polypeptide and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN108409836B (en) |
| WO (1) | WO2019134392A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019134392A1 (en) * | 2018-01-08 | 2019-07-11 | 中国医科大学 | Polypeptide and use thereof |
| CN110330551A (en) * | 2019-08-05 | 2019-10-15 | 中国医科大学 | A kind of cancer of pancreas specific bond peptide and preparation method thereof and purposes |
| CN111253472A (en) * | 2020-04-02 | 2020-06-09 | 中国医科大学 | Novel polypeptide targeting multiple tumor cells and application thereof |
| CN112979757A (en) * | 2019-12-17 | 2021-06-18 | 辽宁中健医药科技有限公司 | Polypeptide of specific target human liver cancer cell |
| WO2023184332A1 (en) * | 2022-03-31 | 2023-10-05 | 深圳先进技术研究院 | Ovary-targeting polypeptide and use thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105198964A (en) * | 2015-10-12 | 2015-12-30 | 国家纳米科学中心 | Tumor targeted polypeptide, and preparation method and application thereof |
| EP3042955A1 (en) * | 2013-09-06 | 2016-07-13 | The University of Tokyo | Use of rhoa in cancer diagnosis and inhibitor screening |
| CN106749527A (en) * | 2016-12-28 | 2017-05-31 | 南京农业大学 | Phage-displayed polypeptides that imidaclothiz antibody specificity is combined and application thereof |
| CN109942682A (en) * | 2017-12-20 | 2019-06-28 | 深圳先进技术研究院 | A kind of CMKLR1 antagonism polypeptide and its derivative and application |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108409836B (en) * | 2018-01-08 | 2020-04-21 | 中国医科大学 | Polypeptide and application thereof |
| CN108530520B (en) * | 2018-04-19 | 2021-02-19 | 福建师范大学福清分校 | Manganese ion binding peptide, screening method thereof and method for detecting affinity performance |
-
2018
- 2018-03-15 CN CN201810214130.3A patent/CN108409836B/en active Active
- 2018-09-14 WO PCT/CN2018/105631 patent/WO2019134392A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3042955A1 (en) * | 2013-09-06 | 2016-07-13 | The University of Tokyo | Use of rhoa in cancer diagnosis and inhibitor screening |
| CN105198964A (en) * | 2015-10-12 | 2015-12-30 | 国家纳米科学中心 | Tumor targeted polypeptide, and preparation method and application thereof |
| CN106749527A (en) * | 2016-12-28 | 2017-05-31 | 南京农业大学 | Phage-displayed polypeptides that imidaclothiz antibody specificity is combined and application thereof |
| CN109942682A (en) * | 2017-12-20 | 2019-06-28 | 深圳先进技术研究院 | A kind of CMKLR1 antagonism polypeptide and its derivative and application |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019134392A1 (en) * | 2018-01-08 | 2019-07-11 | 中国医科大学 | Polypeptide and use thereof |
| CN110330551A (en) * | 2019-08-05 | 2019-10-15 | 中国医科大学 | A kind of cancer of pancreas specific bond peptide and preparation method thereof and purposes |
| CN110330551B (en) * | 2019-08-05 | 2023-02-28 | 中国医科大学 | Pancreatic cancer specific binding peptide and preparation method and application thereof |
| CN112979757A (en) * | 2019-12-17 | 2021-06-18 | 辽宁中健医药科技有限公司 | Polypeptide of specific target human liver cancer cell |
| CN112979757B (en) * | 2019-12-17 | 2024-02-13 | 沈阳医健生命科技有限责任公司 | Polypeptide of specific targeting human liver cancer cell |
| CN111253472A (en) * | 2020-04-02 | 2020-06-09 | 中国医科大学 | Novel polypeptide targeting multiple tumor cells and application thereof |
| WO2023184332A1 (en) * | 2022-03-31 | 2023-10-05 | 深圳先进技术研究院 | Ovary-targeting polypeptide and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019134392A1 (en) | 2019-07-11 |
| CN108409836B (en) | 2020-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108409836A (en) | A kind of polypeptide and application thereof | |
| CN108640976A (en) | A kind of polypeptide with human colon cancer cell specific binding | |
| CN102264755A (en) | Vegfr-1/nrp-1 targeting peptides | |
| CN108341854A (en) | A kind of novel polypeptide of cancer target and application thereof | |
| Zhang et al. | Panning and identification of a colon tumor binding peptide from a phage display peptide library | |
| CN108715616A (en) | The Chimeric antigen receptor method and purposes of targeting humanized mesothelin | |
| US20050260133A1 (en) | Strategy for designing patient-specific anti-cancer drugs | |
| CN111253472B (en) | Novel polypeptide targeting multiple tumor cells and application thereof | |
| CN104017049A (en) | Tumor-specific targeting polypeptide and application thereof | |
| KR20160135571A (en) | Peptides for targeting tumor cells and uses thereof | |
| CN110330551B (en) | Pancreatic cancer specific binding peptide and preparation method and application thereof | |
| CN101671396B (en) | Vascular endothelial growth factor specifically combined with collagen and application thereof | |
| CN108178783B (en) | Tumor blood vessel and M1 type macrophage targeting peptide and application thereof | |
| CN108624608A (en) | Target the preparation method and purposes of the forth generation Chimeric antigen receptor of mesothelin | |
| CN104593359B (en) | The polypeptide of Transitional cell carcinoma cell line BIU87 specific bindings and its application | |
| CN106589066A (en) | Human ovarian carcinoma cell specifically binding polypeptide and application thereof | |
| CN103882057B (en) | Carry structure and the application thereof of p21ras single-chain antibody gene tomour specific adenoviral vectors | |
| CN102746402A (en) | Fully-humanized anti-human prolactin receptor single-chain antibody and application thereof | |
| CN105713070A (en) | Polypeptide specifically bound with human breast cancer cell and application thereof | |
| CN101838310A (en) | Basic fibroblast growth factor epitope simulative peptide T3 and application thereof | |
| CN108285479B (en) | Heptapeptide and application thereof in preparation of product for treating and/or diagnosing cervical cancer | |
| CN110862459A (en) | HPV16E7 affibody-loaded granzyme B affoxin targeting molecule and application thereof | |
| CN113527429B (en) | Human liver cancer cell specific binding polypeptide and its use | |
| CN105859841B (en) | A kind of pair targets chimeric peptide and its is preparing the application in medicine for anti transfer of tumor | |
| CN105753990B (en) | A kind of fusion protein of vasoactive intestinal peptide and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |